MYC and lymphoma: SVs leading to TAD fusions have been reported among diverse cancer cell lines and tumor samples involving recurrent loci of oncogenes like MYC, TERT, and CCND1. Specifically, the structural landscape of MYC was found to be altered in breast, osteosarcoma, neuroblastoma, lymphoma and pancreatic cancers.